U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H28N2O5
Molecular Weight 424.4895
Optical Activity ( - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENAZEPRIL

SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(CC(O)=O)C2=O

InChI

InChIKey=XPCFTKFZXHTYIP-PMACEKPBSA-N
InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H28N2O5
Molecular Weight 424.4895
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

BENAZEPRIL, (±)- is an impurity referred to as Related Compound B, which is a diastereomer of benazepril, an ACE inhibitor, under the brand name Lotensin used primarily in treatment of hypertension, congestive heart failure, and heart attacks, and also in preventing the renal and retinal complications of diabetes. BENAZEPRIL, (±)- is used as USP Reference Standard.

CNS Activity

Curator's Comment: Benazepril crossed the blood-brain barrier only to an extremely low extent.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LOTENSIN

Approved Use

Amlodipine besylate and benazepril hydrochloride capsules is a combination capsule of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent (1) 1.1 Hypertension Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent.

Launch Date

1991
Primary
BENAZEPRIL HYDROCHLORIDE

Approved Use

Benazepril hydrochloride tablets are indicated for the treatment of hypertension. They may be used alone or in combination with thiazide diuretics.

Launch Date

1991
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
437 pmol/g
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
334 pmol × h/g
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.6 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Other AEs: Headache, Back pain...
Other AEs:
Headache (8.6%)
Back pain (2.6%)
Diarrhoea (0.9%)
Upper respiratory tract infection (3.4%)
Peripheral oedema (1.7%)
Sinusitis (1.7%)
Fatigue (0.9%)
Cough (1.7%)
Arthralgia (0.9%)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (9%)
Fatigue (2%)
Nausea (2%)
Dizziness (2%)
Cough increased (2%)
Sources:
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (3%)
Fatigue (2%)
Nausea (1%)
Dizziness (3%)
Dizziness postural (1%)
Cough increased (2%)
Sources:
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (3%)
Fatigue (2%)
Nausea (1%)
Dizziness (2%)
Dizziness postural (1%)
Cough increased (1%)
Sources:
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Headache, Dizziness...
Other AEs:
Headache (6%)
Dizziness (2%)
Dizziness postural (2%)
Sources:
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Headache, Fatigue...
Other AEs:
Headache (2%)
Fatigue (5%)
Nausea (1%)
Cough increased (1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Arthralgia 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Diarrhoea 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Fatigue 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Cough 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Peripheral oedema 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Sinusitis 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Back pain 2.6%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Upper respiratory tract infection 3.4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Headache 8.6%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Cough increased 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache 9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness postural 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cough increased 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cough increased 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness postural 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache 3%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness postural 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache 6%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cough increased 1%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea 1%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache 2%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue 5%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
PubMed

PubMed

TitleDatePubMed
Sympathomoderating influence of benazepril in essential hypertension.
1992 Apr
Benazepril versus felodipine as supplement to bendroflumethiazide: evaluation by office and ambulatory blood pressure.
1998 Apr
Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits.
1999 Apr
Low Dose Combination Therapy vs. High Dose Monotherapy in the Management of Hypertension.
1999 Nov
Renal protective effects of blocking the intrarenal renin-angiotensin system.
1999 Sep
Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
2000 Jan
Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
2000 Nov
Renin-angiotensin system plays an important role in the regulation of water transport in the peritoneum.
2001
Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
2001 Aug
Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
2001 Aug
Significance of ACE genotypes and medical treatments in childhood focal glomerulosclerosis.
2001 Aug
Amlodipine/benazepril: fixed dose combination therapy for hypertension.
2001 Jan
Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis.
2001 Jul
Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake.
2001 Jul
Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone.
2001 Jul
The quantitative determination of several inhibitors of the angiotensin-converting enzyme by CE.
2001 Jul
Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report.
2001 Mar
Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency.
2001 Mar
Spectrophotometric determination of benazepril hydrochloride and hydrochlorothiazide in binary mixture using second derivative, second derivative of the ratio spectra and chemometric methods.
2001 May
Prescribing patterns and cost of antihypertensive drugs in an internal medicine clinic.
2001 May-Jun
Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
2001 Nov
Treatment of IgA nephropathy with angiotensin converting enzyme inhibitors: design of a prospective randomized multicenter trial.
2001 Nov-Dec
Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists.
2001 Sep
Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension.
2002
Using ACE inhibitors appropriately.
2002 Aug 1
Kinetics of the acidic and enzymatic hydrolysis of benazepril HCl studied by LC.
2002 Jan 1
Potentiometric and thermal studies of a coated-wire benazepril-selective electrode.
2002 Jan 1
[The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
2002 Jun
Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension.
2002 Jun
Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting.
2002 Jun
Self-measured systolic blood pressure in the morning is a strong indicator of decline of renal function in hypertensive patients with non-diabetic chronic renal insufficiency.
2002 May
The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats.
2002 Nov
Rhabdomyolysis with concurrent atorvastatin and diltiazem.
2002 Oct
Pregnancy with prolonged fetal exposure to an angiotensin-converting enzyme inhibitor.
2002 Oct-Nov
Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion.
2002 Sep
Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
2003 Apr
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
2003 Apr
[Effect of the compound of traditional Chinese drugs on gene expression of renal endothelin and its receptor of experimental diabetic nephropathy].
2003 Feb
Quantitative determination of benazepril and benazeprilat in human plasma by gas chromatography-mass spectrometry using automated 96-well disk plate solid-phase extraction for sample preparation.
2003 Jan 5
Rationale for combination therapy as initial treatment for hypertension.
2003 Jul-Aug
Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
2003 Mar
Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor.
2003 Mar
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
2003 Mar
Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
2003 Mar
Systemic contact dermatitis due to captopril without cross-sensitivity to fosinopril, quinapril and benazepril.
2004
Effects of co-administration of urokinase and benazepril on severe IgA nephropathy.
2004 Apr
Hypertensive patients from two rural Chinese counties respond differently to benazepril: the Anhui Hypertension Health Care Study.
2004 Feb
Patents

Sample Use Guides

The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. The usual maintenance dosage range is 20-40 mg per day administered as a single dose or in two equally divided doses. A dose of 80 mg gives an increased response, but experience with this dose is limited.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: In the isolated rabbit aorta the vasocontraction induced by PGF2 alpha was competitively antagonized at 10(-5)-10(-4) mol/l, while vascular responses induced by PGE1, PGE2 or PGI2 was inhibited at 3 x 10(-4) mol/l of benazepril. https://www.ncbi.nlm.nih.gov/pubmed/2080946
Benazepril inhibited both adrenaline-stimulated aortic PGI2 synthesis (25 pg mg -1 min-1) and carbachol-stimulated urinary bladder PGI2 synthesis (20 pg mg -1 min-1) in dose-dependent manners. IC50 (concentrations of antagonist at which agonist-stimulated PGI2 synthesis was inhibited by 50%) was 8 x 10-5.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:29:36 GMT 2025
Edited
by admin
on Mon Mar 31 18:29:36 GMT 2025
Record UNII
UDM7Q7QWP8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENAZEPRIL
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
BENAZEPRIL SANDOZ
Preferred Name English
benazepril [INN]
Common Name English
CIBACEN WS
Common Name English
BENAZEPRIL [MI]
Common Name English
Benazepril [WHO-DD]
Common Name English
1H-1-Benzazepine-1-acetic acid, 3-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)-
Systematic Name English
C09AA07
Code English
BENAZEPRIL [VANDF]
Common Name English
BRIEM
Common Name English
BENAZEPRIL [EMA EPAR VETERINARY]
Common Name English
(3S)-3-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid
Systematic Name English
CGS-14824A
Code English
CIBACENE
Common Name English
FORTEEKOR
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175562
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
EMA VETERINARY ASSESSMENT REPORTS FORTEKOR PLUS [AUHTORIZED]
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
NDF-RT N0000000181
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
WHO-ATC C09AA07
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
NCI_THESAURUS C247
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
WHO-VATC QC09AA07
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
WHO-ATC C09BA07
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
WHO-VATC QC09BA07
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
LIVERTOX NBK548659
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
Code System Code Type Description
INN
6129
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
WIKIPEDIA
BENAZEPRIL
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
RXCUI
18867
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY RxNorm
LACTMED
Benazepril
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
MESH
C044946
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
MERCK INDEX
m2303
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY Merck Index
EVMPD
SUB05700MIG
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
SMS_ID
100000090490
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
DRUG BANK
DB00542
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
PUBCHEM
5362124
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
ChEMBL
CHEMBL838
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
IUPHAR
6374
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
CHEBI
3012
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
EPA CompTox
DTXSID5022645
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
FDA UNII
UDM7Q7QWP8
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
DRUG CENTRAL
299
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
CHEBI
3011
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
CAS
86541-75-5
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
NCI_THESAURUS
C61645
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
DAILYMED
UDM7Q7QWP8
Created by admin on Mon Mar 31 18:29:36 GMT 2025 , Edited by admin on Mon Mar 31 18:29:36 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
Related Record Type Details
PARENT -> IMPURITY
Impurity C: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.3 per cent)
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC